IGF1R and ovarian carcinoma: An example is B003-2A, a recently developed IGF-1R anti-idiotypic antibody antagonist, which abrogated the IGF-1R-mediated proliferation of ovarian cancer cells in vivo and in vitro and overcame resistance to cisplatin in ovarian cancer cell lines (64, 74).